
    
      The study was terminated on 11 March 2009 because the independent Data Monitoring Committee
      determined that the study had met its primary endpoint in demonstrating improvement in
      progression-free survival. The decision to terminate the trial was not based on safety
      concerns related to sunitinib administration.
    
  